NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $5.08 by $0.41. The biopharmaceutical company earned $1.51 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 23.54% and a return on equity of 29.92%. The company's revenue for the quarter was up 14.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.92 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

24 brokerages have issued 1-year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $290.00 to $593.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $421.1667 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Ratings for Regeneron Pharmaceuticals.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Regeneron Pharmaceuticals include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY).

Media headlines about REGN stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Regeneron Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include SANOFI (95.60%), Manning & Napier Group LLC (0.48%), Assenagon Asset Management S.A. (0.11%), Bank of Montreal Can (0.04%), Retirement Systems of Alabama (0.03%) and Nippon Life Global Investors Americas Inc. (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Westpac Banking Corp, Nisa Investment Advisors LLC, Boston Advisors LLC, Nippon Life Global Investors Americas Inc., Calamos Advisors LLC, Gateway Investment Advisers LLC and Retirement Systems of Alabama. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Manning & Napier Group LLC, Financial & Investment Management Group Ltd., Essex Investment Management Co. LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, Cito Capital Group LLC and Amalgamated Bank. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $365.98.

Regeneron Pharmaceuticals has a market capitalization of $39.36 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]